pI: 6.1057 |
Length (AA): 602 |
MW (Da): 67523 |
Paralog Number:
1
Signal peptide: N | GPI Anchor: | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Mid 40-60% percentile | Procyclic. | Siegel TN |
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Lower 20-40% percentile | Bloodstream Form. | Siegel TN |
Siegel TN | Genome-wide analysis of mRNA abundance in two life-cycle stages of Trypanosoma brucei and identification of splicing and polyadenylation sites. |
Ortholog group members (OG5_128616)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT5G60790 | ABC transporter F family member 1 |
Brugia malayi | Bm1_18510 | ATP-binding cassette, sub-family F, member 2 |
Candida albicans | CaO19.9729 | ATP-binding cassette protein similar to S. cerevisiae YER036C |
Candida albicans | CaO19.2183 | ATP-binding cassette protein similar to S. cerevisiae YER036C |
Caenorhabditis elegans | CELE_T27E9.7 | Protein ABCF-2 |
Dictyostelium discoideum | DDB_G0284047 | ABC transporter-related protein |
Drosophila melanogaster | Dmel_CG9281 | CG9281 gene product from transcript CG9281-RB |
Homo sapiens | ENSG00000033050 | ATP-binding cassette, sub-family F (GCN20), member 2 |
Leishmania braziliensis | LbrM.19.1110 | ABC transporter, putative |
Leishmania donovani | LdBPK_190800.1 | ATP-binding cassette protein subfamily F, member 2, putative |
Leishmania infantum | LinJ.19.0800 | ATP-binding cassette protein subfamily F, member 2, putative |
Leishmania major | LmjF.19.0800 | ATP-binding cassette protein subfamily F, member 2, putative |
Leishmania mexicana | LmxM.19.0800 | ABC transporter, putative |
Loa Loa (eye worm) | LOAG_07759 | ATP-binding cassette |
Mus musculus | ENSMUSG00000028953 | ATP-binding cassette, sub-family F (GCN20), member 2 |
Oryza sativa | 4346343 | Os08g0564100 |
Oryza sativa | 4347924 | Os09g0572400 |
Saccharomyces cerevisiae | YER036C | ATP-binding cassette family ATPase ARB1 |
Schistosoma japonicum | Sjp_0306880 | ATP-binding cassette sub-family F member 2, putative |
Schistosoma japonicum | Sjp_0218580 | ko:K06185 ATP-binding cassette, sub-family F, member 2, putative |
Schistosoma mansoni | Smp_040540 | ATP-dependent transporter |
Schmidtea mediterranea | mk4.017271.00 | ATP-binding cassette sub-family F member 2 |
Schmidtea mediterranea | mk4.001072.00 | |
Schmidtea mediterranea | mk4.009907.00 | |
Trypanosoma brucei gambiense | Tbg972.10.18970 | ABC transporter, putative |
Trypanosoma brucei | Tb11.v5.0748 | ABC transporter, putative |
Trypanosoma brucei | Tb927.10.15530 | ABC transport system ATP-binding protein, putative |
Trypanosoma congolense | TcIL3000_10_13320 | ABC transporter, putative |
Trypanosoma cruzi | TcCLB.508897.30 | ABC transport system ATP-binding protein, putative |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.10.15530 this record | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.10.15530 this record | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.10.15530 this record | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.10.15530 this record | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
YER036C | Saccharomyces cerevisiae | inviable | yeastgenome |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
Affected Entity | Phenotypic quality | Occurs in | Occurs at | Evidence | Observed in | Drugs/Inhibitors |
---|---|---|---|---|---|---|
cell proliferation (GO:0008283) | normal (PATO:0000461) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in bloodstream forms (stage 3 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | increased (PATO:0000470) | bloodstream stage trypomastigotes (PLO:0027) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | increased cell proliferation (significant gain of fitness) in bloodstream forms (stage 6 days). | References: | 21363968 | |
cell proliferation (GO:0008283) | normal (PATO:0000461) | procyclic (PLO:0034) | inferred from RNAi experiment (ECO:0000019) | No drug identifiers listed for this gene. | ||
Annotator: | fernan@iib.unsam.edu.ar. | Comment: | normal cell proliferation (no significant loss or gain of fitness) in differentiation of procyclic to bloodstream forms . | References: | 21363968 |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.
Druggability index (range: 0 to 1): 0.5
1 literature reference was collected for this gene.